Katz Philip O, Dunbar Kerry B, Schnoll-Sussman Felice H, Greer Katarina B, Yadlapati Rena, Spechler Stuart Jon
Department of Medicine, Division of Gastroenterology and Hepatology, Jay Monahan Center for Gastrointestinal Health, Weill Cornell Medicine, New York, New York, USA.
Department of Medicine, University of Texas Southwestern Medical Center, Dallas VA Medical Center, Dallas, Texas, USA.
Am J Gastroenterol. 2022 Jan 1;117(1):27-56. doi: 10.14309/ajg.0000000000001538.
Gastroesophageal reflux disease (GERD) continues to be among the most common diseases seen by gastroenterologists, surgeons, and primary care physicians. Our understanding of the varied presentations of GERD, enhancements in diagnostic testing, and approach to patient management have evolved. During this time, scrutiny of proton pump inhibitors (PPIs) has increased considerably. Although PPIs remain the medical treatment of choice for GERD, multiple publications have raised questions about adverse events, raising doubts about the safety of long-term use and increasing concern about overprescribing of PPIs. New data regarding the potential for surgical and endoscopic interventions have emerged. In this new document, we provide updated, evidence-based recommendations and practical guidance for the evaluation and management of GERD, including pharmacologic, lifestyle, surgical, and endoscopic management. The Grading of Recommendations, Assessment, Development, and Evaluation system was used to evaluate the evidence and the strength of recommendations. Key concepts and suggestions that as of this writing do not have sufficient evidence to grade are also provided.
胃食管反流病(GERD)仍然是胃肠病学家、外科医生和初级保健医生诊治的最常见疾病之一。我们对GERD多种表现形式的认识、诊断测试的改进以及患者管理方法都有所发展。在此期间,对质子泵抑制剂(PPI)的审查大幅增加。尽管PPI仍然是GERD的首选药物治疗方法,但多篇出版物对不良事件提出了疑问,引发了对长期使用安全性的质疑,并增加了对PPI过度处方的担忧。有关手术和内镜干预潜力的新数据已经出现。在这份新文件中,我们为GERD的评估和管理提供了最新的、基于证据的建议和实用指南,包括药物治疗、生活方式、手术和内镜管理。推荐分级、评估、制定和评价系统用于评估证据和推荐强度。还提供了截至撰写本文时尚无足够证据进行分级的关键概念和建议。